Drugs / rhuFlt3L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01976585 | Jan 2014 → Nov 2020 | indolent B-cell non-Hodgkin lymphoma | Joshua Brody | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhuFlt3L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01976585 ↗ |
| Known as | CDX-301 | “rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.” NCT01976585 ↗ |
| Modality | Protein / enzyme biologic | “rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.” NCT01976585 ↗ |